Evidence map›Paper›PMID 40012182›Full record

ArticleJournal of biopharmaceutical statistics2025

Sample size determination for a study with variable follow-up time.

Guogen Shan, Yahui Zhang, Xinlin Lu, Yulin Li, Minggen Lu, Zhigang Li

Abstract read
In one paragraph

Article in Journal of biopharmaceutical statistics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Guogen ShanDepartment of Biostatistics, University of Florida, Gainesville, Florida, USA.ORCID 0000-0001-8690-6599
Yahui ZhangDepartment of Biostatistics, University of Florida, Gainesville, Florida, USA.
Xinlin LuDepartment of Biostatistics, University of Florida, Gainesville, Florida, USA.
Yulin LiDepartment of Biostatistics, University of Florida, Gainesville, Florida, USA.
Minggen LuSchool of Community Health Sciences, University of Nevada, Reno, NV, USA.
Zhigang LiSchool of Community Health Sciences, University of Nevada, Reno, NV, USA.

Funding

RECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6M
Alzheimer's Disease: New Trial Designs for Emerging ChallengesR01AG070849 · NIA · UNIVERSITY OF NEVADA LAS VEGAS · PI SHAN, GUOGEN · 2021 to 2025
$1.5M
Application of deep learning and novel survival models to predict MCI-to-AD dementia progressionR03AG083207 · NIA · UNIVERSITY OF FLORIDA · PI SHAN, GUOGEN · 2023 to 2024
$164k
NIA NIH HHS R01 AG070849NIA NIH HHS R03 AG083207NIA NIH HHS U19 AG010483
6 · The paper itself

Abstract

For a study to detect the outcome change at the follow-up visit from baseline, the pre-test and post-test design is commonly used to assess the treatment-control difference. Several existing methods were developed for sample size calculation including the subtraction method, analysis of covariance (ANCOVA), and linear mixed model. The first two methods can be used when the follow-up time is the same as scheduled. Although the linear mixed model can analyze the repeated measures by including the actual visit time to account for the variability of the follow-up time, it often assumes a constant treatment-control difference at any follow-up time which may not be correct in practice. We propose to develop a new statistical model to compare the treatment-control difference at the planned follow-up time while controlling for the follow-up time variation. The spline functions are used to estimate the trajectories of the treatment arm and the control arm. We compared the performance of these methods with regards to type I error rate, statistical power, and sample size under various conditions. These four methods all control for the type I error rate. The new method and the ANCOVA method are often more powerful than the other two methods, and they have similar statistical power when a linear disease progression is satisfied. For a study with non-linear disease progression, the new method can be more powerful than the ANCOVA method. We used data from a completed Alzheimer's disease trial to illustrate the application of the proposed method.

Indexed as

Clinical trialpre-test and post-test designrandomized studysample sizespline functionstatistical power

Identifiers

PMID40012182
PMCPMC12353296

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.